We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGY Allergy Therapeutics Plc

0.00 (0.0%)
07 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2.34 1,147,684 16:35:17
Bid Price Offer Price High Price Low Price Open Price
2.10 2.30 2.30 2.20 2.30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 60.95M -51.03M -0.0107 -2.06 104.7M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:17 O 2,500,000 2.40 GBX

Allergy Therapeutics (AGY) Latest News

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-07 17:15:002.402,500,00060,000.00O
2023-12-07 17:15:002.402,500,00060,000.00O
2023-12-07 17:15:002.403,357,70880,584.99O
2023-12-07 16:35:172.34154,0003,603.60UT
2023-12-07 16:23:272.2650,0001,130.00O

Allergy Therapeutics (AGY) Top Chat Posts

Top Posts
Posted at 07/12/2023 08:20 by Allergy Therapeutics Daily Update
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 2.34p.
Allergy Therapeutics currently has 4,758,946,227 shares in issue. The market capitalisation of Allergy Therapeutics is £104,696,817.
Allergy Therapeutics has a price to earnings ratio (PE ratio) of -2.06.
This morning AGY shares opened at 2.30p
Posted at 06/12/2023 13:33 by vergeltung
I wonder why beccasan is posting on this thread; they cannot be a shareholder with the opinions they write - so is beccasan a disinterested third party giving us the benefit of their negative views out of pure altruism? Or do they work for a competitor, maybe even one interested in acquiring AGY at a depressed price?
Posted at 14/11/2023 13:37 by jimmyloser
Whilst this mornings RNS was appreciated, it was no great surprise to me.

A 16% price increase is very welcome and the breakthrough by AGY a company currently based in Britain is nice to see.

Both commercially and medically this is much needed news and I look forward to a continued flow of further upbeat news releases in the weeks ahead.

As all know, I have remained optimistic, today was the first step in the right direction.


Potentially, what's next for us?

Positive trial results imminently? - Achieved, thanks.✔
Progress on peanuts.?
Successful fund raising?
Expansion of markets?

“This time next year, who knows”😊;😊
Posted at 01/11/2023 17:16 by jimmyloser
Thanks Vergeltung,
Do you think that a share price of £1.45p will make this even more illiquid? I was thinking with only a handful of shares in the hands of P.I.'s.

Interesting days ahead for us all and that is of course, impo.
Posted at 17/10/2023 10:16 by jpuff
They won't do that for sure. If the CEO retains his job and gets his options reset to the new share price then that will prove in my mind it was all planned and a deliberate sting operation.
Posted at 16/10/2023 16:26 by jimmyloser
Coinbase, thanks. However I am honestly confused by this malarkey. Conjecture I know, but this couldn't have been better stage managed.

We have a company who up and until the quality issue or whatever they are terming it as, was doing well and whose share price (overheated to circa 38p) on the thought of a peanut allergy cure.
Now we have not one, but two 'potential world beaters' and an offer of a penny a share!

Don't be too hard on yourself................I am incandescent (impo)
Posted at 10/8/2023 12:42 by 1kckeith
This company has become some kind of corporate clown, blundering around the AIM stage in enormous comedic shoes, ‘accidentally’ stomping on (non-Insider) shareholders. Good is bad, large is small. Nothing is as it seems.

Our genius board and its advisors have managed to produce a situation where:
1. Investors are not investors. A major Insider Shareholder since years still does not have an Foreign Direct Investor (FDI) clearance.
2. The board is not in control (I). If this FDI approval is not forthcoming the Insider gets the company for nothing; who controls the process? (hint: the Insider! Actually it only needs use ‘reasonable endeavours’ re the FDI)
3. Good is Bad. If AGY too quickly achieves its biggest objective, striven for almost since the company’s foundation - a successful outcome for G306 - it is likely to be disastrous for shareholders.
4. More is less. If, against the odds, shareholders do get to subscribe in the largest fund-raise the company has ever had, AGY will still need more financing within months
5. The Board is not in control (II). AGY is in discussion with ‘certain shareholders’ (hint: the Insiders, SkyGem and Southern Fox) re financing after October. Hmm – who holds all the cards here? (hint: see previous hint)
6. Minus 20% is slight. Amazingly, even after last year’s cretinous shut-down, if AGY produces clinical trial material now it cannot make enough product for sale too, so projected sales will be ‘slightly lower’ than this year’s - which were short-supplied by the ‘short term pause in production’ aka the cretinous shut-down
7. The worthless is prioritised, the Important concealed. Fair value accounting: 33m warrants to buy shares at 30p is worthy of first mention (hint: it’s zero) but the known repayment premium on the Loan Facility comes second and is not quantified (hint: it’s huge at 250% and unaffordable).
8. Heads they win; tails, they don’t lose. The premium is payable if G306 is successful and the last FDI approval is not received by Jan 2024. Or if for any other reason the Equity Financing does not happen. Or if G306 is a failure.

I could go on. Major worries are that October financing (what happens if it pre-dates the Equity Financing? What sort of punitive terms will the Insiders force down our throats when it does happen?) and the slim likelihood of the Open Offer actually happening.

Like most clowns, this one is more terrifying than funny.
Posted at 01/8/2023 14:34 by timbo003
Thanks for your unique insight KmcK, I have sent you a PM via the ADVFN messaging service.

>>>>farmergeorge, I susspect many investors see the current shares as an option (but not an obligation) to increase their stake by 6 fold at the price of 1p/share, so if they buy now at say 4.5p, they can then buy 6 times as many shares at 1p some time later this year (hopefully!), so even if the share price falls back to say 2p/share after the fund raise, they will still be in the money overall assuming they had taken up the offer in full.
Posted at 01/8/2023 12:18 by 1kckeith
Yes, thanks Timbo, for attending and sharing the feedback.

Unsurprising that Mr Llobet couldn't be bothered to attend in person. I understand this is how he likes to manage our company - remotely from Spain - and it is an important contributory factor to the inability to engage an outside CFO. Although it is quite right that he should not expect any 'performance' related pay, can anyone seriously claim that he brought value to the company to justify his 'basic' £388k over the last 12 months? Watch out for his LTIPs being revalued to match the new low share price he brought about, if ever the Equity Financing and Open Offer do go ahead.

On your excellent question re stock-building prior to the shut-down, the answer to it is somewhat at odds with how this, the cause of so much, has been presented by the company to date. The 4 October announcement was headed 'Allergy Therapeutics proactively initiates a short-term pause in UK manufacturing to optimise quality systems and accelerate capacity improvements' and went on 'The partial pause in production follows an internal review of current operating processes and is part of the Group's previously communicated ongoing programme to improve the robustness of its quality systems and build capacity across its manufacturing facilities.' This all sounds very discretionary (and therefore either profoundly stupid - timing an 'ongoing programme' for the peak pre-seasonal manufacturing period - or a deliberate act of self-sabotage). I cannot see the MHRA referred to anywhere in the 6 April statement and indeed the directors have explicitly said the shutdown was not regulator-driven. Something's amiss, and if the announcements have been misleading it is not just the board but also the NOMAD and corporate lawyer who need to consider their positions.

As to the second of your questions, of course the Equity Financing at 1p is immutable - this hyper-dilutive funding is how the insider consortium is getting the company for a song. Abbott and other shareholders who do not take the Open Offer are diluted 7:1 and over a quarter (£10m plus interest accruing at over 8% for the February loan, £xm plus interest at 18% on the Facility from April) of the 'new money' raised at 1p is in fact used to repay the insiders' own loans. It is the economics of this that sets alarms ringing.

The answer you were given on the FDI applications is very troubling. If the FDI clearances are not secured, the Equity Financing cannot go ahead. If it does not the company is insolvent and under the terms of the Facility Agreement AGY is essentially handed to the insider consortium for no further consideration.
Furthermore, if the FDI applications are still open (and therefore the Equity Financing has not occurred) when positive G306 results are announced, again under the terms of the Facility Agreement the company incurs obligations that will equally result in insolvency and the creditors - the insiders Southern Fox and SkyGem - get our company without paying us. The question is: who is in charge of delivering the FDI clearances? Hopefully not the insiders themselves, nor our proven highly competent executives.

On the value, at 3p (where it is as I write) the company is capitalised at some £20m. After the recapitalisation, when the number of shares in issue will grow by over 4bn to be 4.75bn, the market cap at 3p will be approximately £140m - equivalent to 22p prior to this fiasco. As the shares were trading in the range 20-30p I suppose this is a supported valuation and a price in the range 3-4p after everything settles is to be expected. Of course the same team remaining in charge after this display of rank incompetence might well impact on the company's reputation and perceived value.
Posted at 31/7/2023 19:58 by timbo003
AGM Report

Today's AGM was held at the offices of the company’s solicitors, Cooley (UK) which is located at 22 Bishopgate EC2N 4BQ, it took quite a while to gain access due to various security measures, so if you ever visit anyone in that that building make sure you let them know ahead of your arrival. When I arrived I commented to Peter Jensen (PJ) that I had received no information from AJ Bell (where I hold most of my AGY shares) about the meeting and I was only aware of the meeting through holding a small number of shares as certificates which meant I got a notification through snail mail. PJ then introduced me to the company secretary (Karley Cheeseman) who said she would look into the matter, but judging by the low attendance at the meeting (I was the only retail shareholder present) I suspect I was not the only retail shareholder who had not been informed about the meeting.

There were three directors present all non-execs: Peter Jensen, Mary Tavener and Anthony Parker (Southern Fox). Apparently Manuel Llobet (CEO) and Simon Shen (ZQ Capital) joined by video link, but I couldn’t see them and they didn’t appear to participate in the proceedings

There were only two resolutions put to shareholders on this occasion, the first was to approve the accounts and the second was to approve the remuneration report. Having just perused the section on director’s remuneration I had a question regarding the performance related portion of the director’s remuneration. For the year in question the CEO was paid approximately £664k, which comprised £388k basic and £276k performance related, so I questioned whether there should have been a performance related payment for any of the executive directors given the appalling share price performance last year. PJ responded by saying that financial year 2022 ended in June 2022 and the factory shut down occurred after the end of the financial year 2022, however for the subsequent year the performance related payment for the CEO would be zero. That seemed like a satisfactory response to me, so I voted to approve resolution 1 and 2.

PJ then closed the formal meeting and allocated me about 15 minutes to ask questions about the business. Given the time constraint I had questions on just two topics, 1) the background to the shutdown last year and the apparent lack of forward planning and contingency plans 2) the forthcoming open offer to shareholders.

Shutdown: I questioned why they hadn’t stockpiled product before the shutdown or put in place other contingency plans. PJ responded by saying that everything they could say on the matter was laid out in the RNS statements dated 6th April 2022, they were not able to expand on that. It was not through choice they shut down when they did, but it was necessary to do so due to regulatory (MHRA) concerns.

Fund raise: I commented that now the share price had risen considerably above the proposed 1p open offer price, and then asked whether they would consider modifying the offer to raise the same amount of money but by issuing (for example) half the number of shares at 2p/share. This would be of particular benefit to shareholders who were not able to participate in the forthcoming raise for whatever reason. PJ turned to the Lawyer (Simon from Cooley UK) to answer that one.

Apparently it is not possible as legal documents have now been signed by the company and proposed funders regarding the proposals for a raise at 1p/share. PJ then took the opportunity to state that he intended to take up the offer in full with his 300K shares, I responded by saying that I intended to do likewise but with a smaller shareholding and allocation. I then asked for confirmation that there would be no funds raised from new outside investors (i.e. no accompanying placing which may attract short term flippers), PJ confirmed there would be no accompanying placing. I also asked whether ordinary shareholders would be able to apply for additional excess shares in addition to their basic allocation, the answer was no, all shares not taken up in the open offer would be purchased by ZQ Capital who are underwriting the offer.

After the meeting had come to an end, Simon (the lawyer) filled in a couple more gaps on the funding: The open offer cannot/will not take place until they have foreign direct investment (FDI) clearance from four Jurisdictions (interestingly the UK is not one of the four). In theory this should be easy (especially considering the nature of AGY’s business), but in practice it is more prolonged and complicated than anticipated. The company will issue RNS statements on this should there be any significant developments on this which could affect timings.
Posted at 08/12/2022 08:16 by wizzkid211
Allergy Therapeutics Plc (LSE)

Allergy Therapeutics Share News (AGY)
Follow AGYBuySell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
0.00 0.0% 13.25 13.00 13.50 0.00 19:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.3 3.7 0.5 29.4 85
Allergy Therapeutics PLC Key updates on Grass MATA MPL and VLP Peanut
08/12/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 8 December 2022

Click Here for more Allergy Therapeutics Charts.

RNS Number : 9931I

Allergy Therapeutics PLC

08 December 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics announces key updates on Grass MATA MPL

and VLP Peanut clinical programmes

Update on production and funding

- Innovative short-course grass pollen immunotherapy with best-in-class potential
- If successful, Grass MATA MPL will be the first subcutaneous and aluminium -- free short-course allergy immunotherapy approved in the US

- Topline safety & efficacy data for Grass MATA MPL expected Q4 2023
- Safety, tolerability and efficacy data for VLP peanut expected 2023
8 December 2022 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, t hat aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Grass MATA MPL incorporates MicroCrystalline Tyrosine ("MCT(R) ") adsorbed allergoids, and the innovative adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only requires patients to receive six injections prior to the grass allergy season to be protected.

The pivotal Phase III G306 trial is a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of Grass MATA MPL. The clinical trial will be conducted in the US and Europe at approximately 120 clinical trial sites. Data readout is planned for Q4 2023.

Previously announced top-line results from the G309 exploratory field trial showed meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season.

In addition, the first subjects have been screened and are poised to receive the Group's innovative, short-course peanut allergy vaccine candidate, VLP Peanut in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy. Plans remain on track for data in 2023.

Update on production and funding

Further to the announcement on the 28(th) October, work is continuing on cost control and tight capital management following the impact of the pause in production. This includes reviewing all funding options and managing the working capital of the Group.

Manuel Llobet, CEO of Allergy Therapeutics, commented: " The start of our pivotal Phase III G306 trial investigating the efficacy and safety of our Grass MATA MPL marks the culmination of our efforts to bring this innovative treatment to millions of patients affected by grass allergies in both the US and Europe. We were encouraged by the results of our short-course grass pollen immunotherapy in the highly successful G309 exploratory field trial and look forward to advancing the development of this innovative treatment. The start of the VLP Peanut PROTECT trial is a significant milestone and a testament to the hard work of the Allergy Therapeutics team, developing innovative approaches that have the potential to transform the way we treat and manage allergies."

More information about the Phase III G306 Grass MATA MPL trial can be found on under the identifier NCT05540717 .

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduces the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -
Allergy Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |